References
Deitel M. The obesity epidemic (editorial). Obes Surg. 2006;16:377–8.
Eades MR, Eades MD. Protein Power. New York: Bantam, 1996 (ISBN 0553574752).
Brody H. The other side of Eden: hunter–gatherers, farmers and the shaping of the world. UK: Faber & Faber, 2002 (ISBN 10:057120502X).
Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34:362–6.
Jenkins DJ, Kendall CW, Augustin LS, et al. Glycemic index: overview of implications in health and disease. Am J Clin Nutr 2002;76:266S–73S.
Baier LJ, Hanson RL. Genetic studies of the etiology of type 2 diabetes in Pima Indians. Diabetes. 2004;53:1181–6.
Reaven GM. The individual components of the metabolic syndrome: is there a raison d’etre? J Am Coll Nutr 2007;26:191–5.
Sanderson I, Deitel M. Insulin response in patients receiving concentrated infusions of glucose and casein hydrolysate for complete parenteral nutrition. Ann Surg. 1974;179:387–94.
Gumbs AA, Modlin AM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005;15:462–73.
Wickremesekera K, Millor G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15:474–81.
Sanderson I, Deitel M, Bojm MA. The handling of glucose and insulin response before and after weight loss with jejuno-ileal bypass: a preliminary report. JPEN 1983;7:274–6.
Deitel M, Sidhu PS, Stone E. Effect of vertical banded gastroplasty on diabetes in the morbidly obese. Obes Surg 1991;1:113–4. (abstr).
Keith SH, Mason EE, Scott DH, et al. Serum insulin and glucose levels, and insulin binding kinectics, in morbid and super obese patients undergoing vertical banded gastroplasty. Obes Surg. 1991;1:112. (abstr).
Smith SG, Edwards CB, Goodman GM. Changes in diabetic management after Roux-en-Y gastric bypass. Obes Surg. 1996;6:345–8.
Halverson JD, Kramer J, Cave A, et al. Altered glucose tolerance, insulin response, and insulin sensitivity after massive weight reduction subsequent to gastric bypass. Surgery. 1982;92:235–40.
Deitel M. The early effect of bariatric operations on diabetes (commentary). Obes Surg. 2002;12:349.
Dixon JB, Dixon AF, O’Brien PE. Improvement in insulin sensitivity and beta cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diab Med. 2003;20:127–34.
Burstein R, Epstein Y, Charuzi I, et al. Glucose utilization in morbidly obese subjects before and after weight loss by gastric bypass operation. Int J Obes. 1995;19:558–61.
Pories WJ. Why does the gastric bypass control type 2 diabetes mellitus? Obes Surg. 1992;2:303–13.
Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.
Lamounier RN, Pareja JC, Tambascia MA, et al. Incretins: clinical physiology and bariatric surgery—correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure. Obes Surg. 2007;17:569–76.
Näslund E, Backman L, Holst JJ, et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg. 1998;8:253–60.
Mason EE. Gastric emptying controls type 2 diabetes mellitus (editorial). Obes Surg. 2007;17:853–5.
Valverde I, Puente J, Martin-Duce A, et al. Changes in glucagons-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg. 2005;15:387–97.
Livingston EH. Lowering the bariatric surgery minimum body mass index threshold. Arch Surg. 2008;143:708–10.
Cohen RV, Schiavon GA, Pinheiro JC, et al. Duodenal–jejunal bypass for the treatment of type 2 diabetes in patients with BMI 22-34: a report of 2 cases. Surg Obes Relat Dis. 2007;3:195–7.
Scopinaro N, Papadia F, Marinari G, et al. Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI <35 kg/m2. Obes Surg. 2007;17:185–92.
Melissas J, Daskalakis M, Koukouraki S, et al. Sleeve gastrectomy—a “food limiting” operation. Obes Surg. 2008;18:Oct (in press).
Frühbeck G, Diez-Caballero A, Gil MJ, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg. 2004;14:606–12.
Mason EE. Ileal transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Obes Surg. 1999;9:223–8.
DePaula AL, Macedo ALV, Rossi N, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with body mass index less than 35. Surg Endosc. 2008;22:706–16.
Zimmet P, Turner R, McCarty D, et al. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diab Care. 1999;22:B59–64.
Landin-Olsson M. Latent autoimmune diabetes in adults. Ann NY Acad Sci. 2002;958:112–6.
Seisser J. Latent (slowly progressing) autoimmune diabetes in adults. Curr Diab Rep. 2008;8:94–100.
Brophy S, Yderstraede K, Mauricio D, et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diab Care. 2008;31:439–41.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitor in type 2 diabetes. Lancet. 2006;368(9548):1696–705.
Madsbad S, Krarup T, Deacon CF, et al. Glucagon-like peptide receptor agonists and dipeptyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11:491–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deitel, M. Surgery for Diabetes at Lower BMI: Some Caution. OBES SURG 18, 1211–1214 (2008). https://doi.org/10.1007/s11695-008-9674-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-008-9674-9